AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...

Biotech stocks are gaining momentum as weight-loss drugs, pipeline depth and clinical data drive renewed growth optimism.

Krystal Biotech is engaged in developing genetic medicines. The biotech stock is near a buy point with earnings due soon.

2025 was a catalyst year for biotech and drug stocks. While the year began on a cautious note for the sector due to concerns over potential tariffs on pharmaceutical imports, the sector rebounded in ...

U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...

After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a strong year for select stocks. Improved policy clarity following most large ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

On December 24, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that healthcare has become the top-performing sector over the last 3 ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher. “Biotech was a coiled spring following several quarters of underperformance,” Dr. Terry Smith, ...